{"id":85409,"date":"2026-09-22T18:10:00","date_gmt":"2026-09-22T18:10:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=85409"},"modified":"2026-09-23T01:24:20","modified_gmt":"2026-09-23T01:24:20","slug":"global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/","title":{"rendered":"Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight"},"content":{"rendered":"<p><em>The Alzheimer\u2019s disease biomarker market is experiencing steady growth, driven by the rising prevalence of Alzheimer\u2019s disease and dementia, increasing emphasis on early and accurate diagnosis, and the growing adoption of biomarker-based approaches in disease management. The market is also benefiting from rapid advancements in blood-based biomarkers, particularly phosphorylated tau (p-tau) and amyloid-beta assays, which offer less invasive and more accessible alternatives to cerebrospinal fluid testing and PET imaging.<\/em><\/p>\n<p align=\"justify\">New York, USA, Sept.  22, 2026  (GLOBE NEWSWIRE) &#8212; <b>Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight<\/b><\/p>\n<p align=\"justify\"><b><i>The Alzheimer\u2019s disease biomarker market is experiencing steady growth, driven by the rising prevalence of Alzheimer\u2019s disease and dementia, increasing emphasis on early and accurate diagnosis, and the growing adoption of biomarker-based approaches in disease management. The market is also benefiting from rapid advancements in blood-based biomarkers, particularly phosphorylated tau (p-tau) and amyloid-beta assays, which offer less invasive and more accessible alternatives to cerebrospinal fluid testing and PET imaging.<\/i><\/b><\/p>\n<p align=\"justify\">DelveInsight\u2019s Alzheimer\u2019s Disease Biomarker Market Insights report provides the current and forecast market analysis, individual leading Alzheimer\u2019s disease biomarker companies\u2019 market shares, challenges, Alzheimer\u2019s disease biomarker market drivers, barriers, trends, and key Alzheimer\u2019s disease biomarker companies in the market.<\/p>\n<p align=\"justify\"><b>Alzheimer\u2019s Disease Biomarker Market Summary<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\"><b>2025 Alzheimer\u2019s Disease Biomarker Market Size: <\/b>USD 2.2 Billion<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>2034 Projected Alzheimer\u2019s Disease Biomarker Market Size: <\/b>USD 4.7 Billion<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Alzheimer\u2019s Disease Biomarker Market Growth Rate (2026-2034): ~<\/b>9%\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Largest Alzheimer\u2019s Disease Biomarker Market: <\/b>North America<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Largest Biomarker Segment:<\/b> Amyloid Biomarkers Category<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Key Companies in the Alzheimer\u2019s Disease Biomarker Market:<\/b> Fujirebio, Roche Diagnostics, Quanterix, Abbott Laboratories, Siemens Healthineers, Beckman Coulter Diagnostics, Sysmex Corporation, Revvity (PerkinElmer), Bio-Techne (R&amp;D Systems), Thermo Fisher Scientific, Merck KGaA (Sigma-Aldrich), and others<\/li>\n<\/ul>\n<p align=\"justify\">To read more about the latest highlights related to the Alzheimer\u2019s disease biomarker news, get a snapshot of the key highlights @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yfB7YEqwbV6DB1RuTyyBkdoDtr7ZzRjpERKjNIwusMoMoYaujU9kD32OUBzK6PWIsogJGV8X2NbWx6wq8rb_QPKNximGiyXgv-ASQ3nkBe7z1YSXW3sjE3RJSRNf6LIHbrLmyHIlhvc0zNHDlmppsm00HwAEs1rqlRgHq8ra9tzNUsHiBBshv0gcHrZM07GWlnJQKxmuBSvJygGZ0SUa0Jyp218M-y4SFbJ15JAihGI4DIeBzXYMvPV38t8OuRFUtOzL7jvgidSBXnbOF4wg4CJSQXtDY1eg7fqHyg_GV1rSZH7xRaEd2Ol7iqx_G2SMc2GwoA_gX3XwAhjb1Jhyog==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-biomarker-market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Key Factors Contributing to the Rise in Growth of the Alzheimer\u2019s Disease Biomarker Market<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\"><b>Rising Prevalence of Alzheimer\u2019s Disease: <\/b>The growing global burden of Alzheimer\u2019s disease, particularly among aging populations, is increasing the demand for accurate and timely diagnostic tools. Biomarkers are gaining importance in identifying disease-related changes before significant cognitive decline occurs.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Growing Geriatric Population: <\/b>The expansion of the elderly population worldwide is contributing to a higher incidence of Alzheimer\u2019s disease and other dementias. This demographic shift is creating greater demand for biomarker-based screening, diagnosis, and disease monitoring.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Advancements in Biomarker Technologies:<\/b> Rapid developments in blood-based biomarkers, cerebrospinal fluid (CSF) analysis, neuroimaging, and molecular diagnostic technologies are improving the accuracy and accessibility of Alzheimer\u2019s disease detection. These innovations are supporting broader adoption of biomarker testing.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Increasing Adoption of Blood-Based Biomarkers:<\/b> Blood-based biomarkers such as plasma amyloid-beta and phosphorylated tau are emerging as less invasive and more accessible alternatives to traditional CSF testing and PET imaging. Their potential for cost-effective and scalable testing is expected to accelerate market growth.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Growing Focus on Early and Accurate Diagnosis:<\/b> Early identification of Alzheimer\u2019s disease is becoming increasingly important for patient management and treatment planning. Biomarkers can help detect pathological changes at earlier stages, supporting more precise diagnosis and patient stratification.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Expansion of Disease-Modifying Therapies:<\/b> The development and commercialization of disease-modifying Alzheimer\u2019s therapies are increasing the need for reliable biomarkers to confirm pathology, identify eligible patients, monitor treatment response, and assess disease progression.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Increasing Clinical Research and Drug Development:<\/b> Pharmaceutical and biotechnology companies are increasingly incorporating biomarkers into clinical trials to improve patient selection and evaluate therapeutic efficacy. This growing use of biomarkers across drug-development programs is strengthening market demand.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Rising Healthcare Investment and Diagnostic Infrastructure:<\/b> Increased investment in neurological research, diagnostic laboratories, and advanced healthcare infrastructure is facilitating the adoption of Alzheimer\u2019s biomarker technologies. Greater availability of specialized testing is supporting market expansion across developed and emerging markets.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Growing Awareness Among Healthcare Professionals and Patients:<\/b> Increased awareness of Alzheimer\u2019s disease and the benefits of early diagnosis is encouraging patients and healthcare providers to consider advanced diagnostic approaches. Greater awareness is also supporting the integration of biomarker testing into specialized memory and neurology clinics.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Regulatory and Guideline Support for Biomarker-Based Diagnosis:<\/b> Evolving diagnostic frameworks and regulatory acceptance of biomarker-based approaches are encouraging their integration into clinical practice. Standardization of testing methods and diagnostic criteria is expected to further improve adoption and market penetration.<\/li>\n<\/ul>\n<p><img loading=\"lazy\" decoding=\"async\" alt=\"\" data-mce-style=\"display: block; margin-left: auto; margin-right: auto;\" height=\"420\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/fef8cfb9-b3c2-4f72-b2da-1675c6d24d68\/alzheimer-s-disease-biomarker-market.jpg\" style=\"display:block; margin-left:auto; margin-right:auto;\" width=\"800\" data-dpi=\"96\" data-filename=\"Alzheimer\u2019s-Disease-Biomarker-Market.jpg\" \/><\/p>\n<p align=\"justify\">Get a sneak peek at the Alzheimer\u2019s disease biomarker market dynamics @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ch64I0ft46OYd-p-1E7OAjljTPLzyNN_sEohXE8DfUmoAubPiS_f2aj-UHHSnffVmabIbl-j-VFQvMiforceADJTqVaiu1TGooqyXycI-h0N0NUm_sr1Wxdafm91fzidAegkWgxFWpw17QaPIc4qVYx3sZSF_IIgfxISNnsr0i58T4cmE2Nd76mp_FV1CiwgFi0UJesU0q_aqbj7krYCHr4_e45xw9BRcF5WpBFB3F9wv_GwIl-OjhRWYeaIXEUDNRc-twYZULuoU749PPfuqKTpqtY_Q8f9Y0A2wCyVa1s=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Alzheimer\u2019s Disease Biomarker Market Trends<\/b><\/a><\/p>\n<p align=\"justify\"><b>Regional Alzheimer\u2019s Disease Biomarker Market Insights<\/b><\/p>\n<p align=\"justify\"><b>North America<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">North America captured the largest share of the global Alzheimer\u2019s disease biomarker market in 2025, contributing approximately 41% of total market revenue.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The region\u2019s leading position is supported by its substantial Alzheimer\u2019s disease patient population, with an estimated 7.4 million Americans aged 65 and older living with the disease in 2026, along with highly developed healthcare and diagnostic laboratory infrastructure and the strong presence of major biomarker assay developers and reference laboratories.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Increasing regulatory support from the U.S. FDA is further facilitating the adoption of advanced diagnostic solutions, highlighted by the clearance of Fujirebio\u2019s Lumipulse blood-based amyloid test in May 2025 and Roche\u2019s Elecsys pTau181 plasma test in October 2025.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Leading reference laboratory networks such as Quest Diagnostics and Labcorp also expanded the availability of blood-based biomarker testing during 2025, while evolving CMS reimbursement mechanisms and newly established proprietary laboratory analysis codes are improving payer coverage and accessibility.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In addition, the presence of prominent diagnostic companies, including Abbott Laboratories, Siemens Healthineers, and Beckman Coulter Diagnostics, coupled with the continued development of biomarker-driven clinical trial infrastructure, is expected to sustain North America\u2019s market leadership throughout the forecast period.<\/li>\n<\/ul>\n<p align=\"justify\"><b>Europe<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Europe represents a significant and rapidly evolving market for Alzheimer\u2019s disease biomarkers, supported by increasing emphasis on early and accurate diagnosis, expanding dementia research, and the growing adoption of biomarker-based diagnostic pathways.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The region has established clinical use of cerebrospinal fluid (CSF) biomarkers, including A\u03b242\/A\u03b240, phosphorylated tau (p-tau), and total tau, alongside amyloid PET imaging, particularly in specialized memory and tertiary care centers.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The market is increasingly shifting toward minimally invasive blood-based biomarkers, as plasma p-tau and amyloid assays offer the potential for more accessible, scalable, and cost-effective detection compared with lumbar puncture and PET imaging.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">This transition is being further supported by the growing clinical importance of biomarker confirmation for disease-modifying Alzheimer\u2019s treatments and the recent approval of blood-based testing technologies in Europe.\u00a0<\/li>\n<\/ul>\n<p align=\"justify\"><b>Asia-Pacific<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Asia-Pacific is projected to emerge as the fastest-growing region in the Alzheimer\u2019s disease biomarker market.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The region\u2019s strong growth trajectory is supported by its rapidly aging population, increasing burden of Alzheimer\u2019s disease and dementia, expansion of diagnostic laboratory infrastructure, and rising healthcare expenditure across China, Japan, India, South Korea, and Australia.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Japan, which has one of the world\u2019s oldest populations, is increasingly incorporating advanced biomarker testing into its universal healthcare system.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Meanwhile, China is expanding its network of memory clinics and strengthening standardized guidelines for dementia diagnosis, while India continues to enhance diagnostic laboratory capabilities alongside growing awareness of the benefits of early Alzheimer\u2019s detection.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In addition, regional distributors are forming partnerships with global biomarker assay manufacturers to improve access to blood-based biomarker and immunoassay testing platforms.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Collectively, the growing disease burden, expanding diagnostic infrastructure, and increasing clinical adoption of biomarker-based testing are expected to make Asia-Pacific a key contributor to market growth throughout the forecast period.<\/li>\n<\/ul>\n<p align=\"justify\">To know more about why North America is leading the market growth in the Alzheimer\u2019s disease biomarker market, get a snapshot of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ch64I0ft46OYd-p-1E7OAjljTPLzyNN_sEohXE8DfUmoAubPiS_f2aj-UHHSnffV3NLJQWnCiV6ljEQMXnZqGqpU-Bc-ygMyDnL6UEbi6mXtdfJUCnXsnJSQLaVpXX11ZH8dpLRwYqtoagDUl4JcAu5QQ82U4jcSDJfm1rVsaM1a9cdHByqW-sC8XsXrL7y9zfqxPVlnkWa_b0HyCkvJ82vjv1jcOiVIQy54rlNIzGpO9we0-WxiMZ_vsYg0pDP5SOfbK-uybiJ6aFJyQ6S_bPJzF5TxBBCcswCcbWKkwR0=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Alzheimer\u2019s Disease Biomarker Market Share<\/b><\/a><\/p>\n<p align=\"justify\"><b>Recent Developmental Activities in the Alzheimer\u2019s Disease Biomarker Market<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">In <b>February 2026, Lucent Diagnostics <\/b>(a Quanterix brand) partnered with Life Line Screening to bring advanced blood-based Alzheimer&#8217;s disease biomarker diagnostics to community screening events nationwide.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>early 2026, Fujirebio Diagnostics<\/b> initiated a Class II recall of specific Lumipulse pTau217\/beta-Amyloid 1-42 lots after data presented at the December 2025 Clinical Trials on Alzheimer&#8217;s Disease conference showed elevated false-positive rates linked to a manufacturing issue, with corrected lots subsequently released.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>December 2025, Quanterix Corporation and ALZpath<\/b> supported a landmark Nature-published study using the ALZpath p-Tau-217 Advantage PLUS kit on Quanterix&#8217;s fully automated Simoa HD-X analyzer to establish Alzheimer&#8217;s disease neuropathology prevalence in a population-based cohort of more than 11,000 individuals in Norway.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>October 2025, Roche <\/b>received FDA clearance for its Elecsys phosphorylated tau (pTau) 181 plasma test to help rule out Alzheimer&#8217;s disease in primary care settings.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>August 2025, Labcorp<\/b> completed the nationwide commercial launch of the Lumipulse blood-based Alzheimer&#8217;s disease test, significantly improving accessibility for clinicians and patients across the United States.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>July 2025, Quest Diagnostics<\/b> announced it would offer laboratory testing based on Fujirebio&#8217;s FDA-cleared Lumipulse plasma ratio test through its national network of patient service centers.<\/li>\n<\/ul>\n<p align=\"justify\"><b>What is Alzheimer\u2019s Disease Biomarker?<\/b><\/p>\n<p align=\"justify\">Alzheimer\u2019s disease biomarkers are measurable biological indicators that provide information about the underlying pathological processes associated with the disease. These biomarkers can help detect and characterize Alzheimer\u2019s-related changes, support diagnosis and differential diagnosis, monitor disease progression, and assess responses to emerging therapies. Key biomarkers include amyloid-beta (A\u03b2) plaques, tau pathology, and neurodegeneration or neuronal injury markers. Amyloid-beta biomarkers, such as A\u03b242\/40 ratios in cerebrospinal fluid (CSF) or plasma, indicate amyloid accumulation, while phosphorylated tau (p-tau), including p-tau181 and p-tau217, reflects tau pathology and has emerged as an important indicator of Alzheimer\u2019s disease. Other biomarkers, such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), provide information on neuronal injury and neuroinflammation. Advances in blood-based biomarker testing are increasingly improving the accessibility of Alzheimer\u2019s disease detection and monitoring, potentially enabling earlier identification of individuals at risk and supporting more efficient clinical development of disease-modifying therapies.<\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Alzheimer\u2019s Disease Biomarker Market Report Metrics<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Details<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Coverage<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Global<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Study Period<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2023\u20132034<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Alzheimer\u2019s Disease Biomarker Market CAGR<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">~9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Alzheimer\u2019s Disease Biomarker Market Size by 2034<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">USD 4.7 Billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Alzheimer\u2019s Disease Biomarker Companies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Fujirebio, Roche Diagnostics, Quanterix, Abbott Laboratories, Siemens Healthineers, Beckman Coulter Diagnostics, Sysmex Corporation, Revvity (PerkinElmer), Bio-Techne (R&amp;D Systems), Thermo Fisher Scientific, Merck KGaA (Sigma-Aldrich), and others<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><b>Alzheimer\u2019s Disease Biomarker Market Assessment<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\"><b>Alzheimer\u2019s Disease Biomarker Market Segmentation<\/b>\n<ul type=\"circle\">\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Alzheimer\u2019s Disease Biomarker Market Segmentation By Biomarker Type: <\/b>Amyloid Biomarkers, Tau Biomarkers, Neurodegeneration Biomarkers, Neuroinflammation Biomarkers, Synaptic Dysfunction Biomarkers, and Others<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Alzheimer\u2019s Disease Biomarker Market Segmentation By Sample Type: <\/b>Blood [Plasma\/Serum], Cerebrospinal Fluid [CSF], Urine, Saliva, and Other Biological Fluids<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Alzheimer\u2019s Disease Biomarker Market Segmentation By Technology: <\/b>Immunoassays, Mass Spectrometry, Polymerase Chain Reaction [PCR], Next-Generation Sequencing [NGS], and Others<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Alzheimer\u2019s Disease Biomarker Market Segmentation By Disease Stage: <\/b>Preclinical Alzheimer&#8217;s Disease, Mild Cognitive Impairment [MCI] Due to Alzheimer&#8217;s Disease, Early-Stage Alzheimer&#8217;s Disease, Moderate Alzheimer&#8217;s Disease, and Severe Alzheimer&#8217;s Disease<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Alzheimer\u2019s Disease Biomarker Market Segmentation By End Users: <\/b>Hospitals, Clinical Diagnostic Laboratories, Academic &amp; Research Institutes, and Pharmaceutical &amp; Biotechnology Companies<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Alzheimer\u2019s Disease Biomarker Market Segmentation By Geography<\/b>: North America, Europe, Asia-Pacific, and Rest of World<\/li>\n<\/ul>\n<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Porter\u2019s Five Forces Analysis, Product Profiles, <\/b><b>Case Studies, KOL\u2019s Views, Analyst\u2019s View<\/b><\/li>\n<\/ul>\n<p align=\"justify\">Which MedTech key players in the Alzheimer\u2019s disease biomarker market are set to emerge as the trendsetter explore @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ch64I0ft46OYd-p-1E7OAjljTPLzyNN_sEohXE8DfUmoAubPiS_f2aj-UHHSnffVh-4c6ZJ-KB5z7k-Y8C0nY3oZmOFwdfsoDSNyjw-XlIINebRwanStCAs6z7ThV1yAr3F5ebyEWQIqIRGpI7iSzM7V9clfkhkK-GF_p-8HPJ0fWAlh5B0Qd3qCPEfqiY1-aXmCb-ephpsevC5OXeGxpFSVNJNLILaVHeL6Y2EzudUmpnQO8VhUraF6kYDHEZtoRN4vDAAwOXjAK3i1ebLMnulFaX4SkIhCsxIfLktbuIY=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Alzheimer\u2019s Disease Biomarker Market Analysis<\/b><\/a><\/p>\n<p align=\"justify\"><b>Table of Contents\u00a0<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">1<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Alzheimer\u2019s Disease Biomarker Market Report Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Alzheimer\u2019s Disease Biomarker Market Executive Summary<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Alzheimer\u2019s Disease Biomarker Market Key Factors Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Impact Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Regulatory Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Alzheimer\u2019s Disease Biomarker Market Porter\u2019s Five Forces Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Alzheimer\u2019s Disease Biomarker Market Assessment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Competitive Landscape<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">9<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Startup Funding &amp; Investment Trends<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">10<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Alzheimer\u2019s Disease Biomarker Market Company and Product Profiles<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">11<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">KOL Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">12<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Project Approach<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">13<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">About DelveInsight<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">14<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Disclaimer &amp; Contact Us<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Interested in knowing the Alzheimer\u2019s disease biomarker market share by 2034? Click to get a snapshot of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hbZ9xL_0BmLKjjTyvTTCG7ws9j7KraKDM0G0kqgGAfCnd4mmrvHJ3YlF_FFc19ob8bArAsdcqM3fX02RKGFWGPPuuSG0jXaRE-fOFKvXOrkAxmlxj_VzSBqjjHPVTrCn-XyKWersEW5F8Vsk2MNi-EduTzMFzrmFyN5pVZ7tr_Oezw6lN91hjaxPJhRs03dH8Kwl-mTMC_nXNfC5B4zdDIKikX6LGN3Poo0XgJQ91oRX1-f8thm6po2Zf5A96UEhKt0DlRJQ4cNgzg20LTrs_CUwLTNU5o6h25yVTpXNckY=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Top Alzheimer\u2019s Disease Biomarkers<\/b><\/a><\/p>\n<p align=\"justify\"><b>Related Reports<\/b><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eKga70h99eZNd0kP-DnCOSXHylRRsFnR0ByChRmItHTtKfrNt7Zp1vjsPEsyUq4wQQ5RHrvA3ZuTk9BHRIu1F9koFLRwEIjmboRYPGs9Zl7we8xZq3NpIaxeQaMGWcihcQyLiCSqoZ1JflTUm7AAYrNRIO7-eObnKgxhLgpwttppWKelfzdnowJ5h5jSPJzjKkMUssqhVobbGGu4Oq9pRVNJ52EEMTPdGPyVdoAJe5Ffff831hKs_SDRY5xAwOlqEMAlLXJl1NRjIF5T8DMgoA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Neurological Biomarkers Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Neurological <\/b><b>Biomarkers<\/b><b> Market Insight, Competitive Landscape, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neurological biomarkers companies such as <b>Abbott, Merck KGaA, Quanterix, Bio-Rad Laboratories, Inc., Banyan Biomarkers, Inc., Quanterix, Thermo Fisher Scientific, Fujirebio, Bio-Techne, ADx NeuroSciences NV, F. Hoffmann-La Roche Ltd., BIOM\u00c9RIEUX, Siemens Healthineers, Quibim, C\u2082N Diagnostics,<\/b> and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OOxldpatOn_2qjXzAYYpBlPVb-wwPzLDpU2GeQDgOSQsBhuOOIi1NLP5LcNrA_zHQfnNtLG0uIlVIm8xKxCNbomDSvpxmVFT7u2gBn8vipbwxa-DDW8TTcrXYQusHPSQVy6x2GIR-vD627xrTtRhtPbz8Iiwsujz4X-0ow5iSbyX5UOwkCRXJjhM2Iwu4_Mox4rRPjQl_v9Z_AlxR1rjdshjgzCIKMdadO9FqwU3SpU=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Biomarkers Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Biomarkers<\/b><b> Market Insight, Competitive Landscape, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biomarkers companies such as <b>F. Hoffmann-La Roche Ltd, Merck KGaA, Quibim, Quanterix, Abbott, QIAGEN, Revvity, Laboratory Corporation of America\u00ae Holdings, Charles River Laboratories., Bio-Rad Laboratories, Inc., Eurofins Scientific, BIOM\u00c9RIEUX, Agilent Technologies, Inc., JSR Life Sciences, LLC, MESO SCALE DIAGNOSTICS, LLC., EKF Diagnostics, Celerion, Standard BioTools&#x2122;, R-Biopharm AG, StressMarq Biosciences Inc.,<\/b> and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nafW14wK9f1prvisW7EJphBJ0d0qGWyRVsNZtqfk-EJi1pJYRjhqGWE7dA9jYPMo0V7CpxDXh72wEVF8WDhARXSebrToL2G3u0J7tvqPEMRNSNt3oIOJYwdTFoRsajNpStRn_b4NrNqHB88IRUlW1l_Rlwa1LawzvmuN8_tueD44ByWmMI_2pfYMERZLBNUF1hqRKLTHxH3QKwt-wZcEl1q5FH4LYS7meUOY5z0yE-0nm8crqu-n6KYUS3aBO5IOB0G42DE2vgJDcGVDNm7xtA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Blood-Based Biomarkers Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Blood-Based Biomarkers<\/b><b> Market Insight, Competitive Landscape, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of market trends, market drivers, market barriers, and key blood-based biomarkers companies such as <b>F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Bio-Rad Laboratories, Inc., Quanterix Corporation, Fujirebio Holdings, Inc., Guardant Health, Inc.,<\/b> and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ch64I0ft46OYd-p-1E7OAjWV-SzFRSQbv3Ve35jLXrKnBLd3UwC0T59fr-WbIrHN6RrcY6-FidZSSlbdXi0RI1kZMvDRSkLXQJFQUyVyvshHhN714nfgqq4qpeP4jN68leYeuZSlJZy4oRsiYJHd47zuodUD-K68dro2NdiSLQeNrlztyruLJrpu3T5WhJWo4NMRgllkjsNWsPzCYzxbh4-ozEFmMlre-kSyAq2-HcSoMQlVsX5J6-Bth0buolEn\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Alzheimer&#8217;s Disease Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Alzheimer&#8217;s Disease Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer&#8217;s disease companies, including <b>Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax &amp; KAEL, AC Immune SA, Johnson &amp; Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics<\/b><b>, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kZy2bmEOpdEeSbZ1s8iuL60UOKV3mCm_9jEeVp6K-6A53Yh10YeXwnTXNwMjzvnundY4-QPGOo4-R_uUA87BlvST90eb8W3HzzyMTKq5v8B2SYFFXETGNhJCOcQYseHpCJk5EihNenY0oCoGqJlI8RHYjSujz0MkNfuSAHu_4i0dd1XdBc5UbA2kMSXUQRtJvgUcNoYuA42M1ApMVALYLrZlQHb9DlMtGQuSQ9nIIHk_jM_9fTkAAUHEMXrfQJ_g3KoapJEW-JrNI_msYpaNdg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Agitation in Alzheimer\u2019s Disease Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Agitation in Alzheimer\u2019s Disease Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key agitation in Alzheimer\u2019s disease companies, including <b>IGC Pharma, Suven Life Sciences, Exciva GmbH, Bristol Myers Squibb, Karuna Therapeutics, Otsuka Pharmaceutical, Lundbeck, Axsome Therapeutics<\/b><b>, <\/b>and others.<\/p>\n<p align=\"justify\"><b>About\u00a0DelveInsight<\/b><\/p>\n<p align=\"justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve<b>.<\/b><\/p>\n<pre>CONTACT: Contact Us\n\nShruti Thakur\u00a0\n\ninfo@delveinsight.com\u00a0\n\n+14699457679<\/pre>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/MGQ2ZDI5YmEtZTQ3OC00YTRlLTg2MTctZTNiYzM2OWNlODVjLTEyMDQ5MzgtMjAyNi0wOS0yMi1lbg==\/tiny\/DelveInsight-Business-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Alzheimer\u2019s disease biomarker market is experiencing steady growth, driven by the rising prevalence of Alzheimer\u2019s disease and dementia, increasing emphasis on early and accurate diagnosis, and the growing adoption of biomarker-based approaches in disease management. The market is also benefiting from rapid advancements in blood-based biomarkers, particularly phosphorylated tau (p-tau) and amyloid-beta assays, which [&#8230;]\n","protected":false},"author":1,"featured_media":85410,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-85409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The Alzheimer\u2019s disease biomarker market is experiencing steady growth, driven by the rising prevalence of Alzheimer\u2019s disease and dementia, incre\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-22T18:10:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-23T01:24:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight\",\"datePublished\":\"2026-09-22T18:10:00+00:00\",\"dateModified\":\"2026-09-23T01:24:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/\"},\"wordCount\":2385,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/\",\"name\":\"Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-09-22T18:10:00+00:00\",\"dateModified\":\"2026-09-23T01:24:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/","og_locale":"en_US","og_type":"article","og_title":"Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight","og_description":"The Alzheimer\u2019s disease biomarker market is experiencing steady growth, driven by the rising prevalence of Alzheimer\u2019s disease and dementia, incre","og_url":"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-09-22T18:10:00+00:00","article_modified_time":"2026-09-23T01:24:20+00:00","og_image":[{"width":800,"height":420,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight","datePublished":"2026-09-22T18:10:00+00:00","dateModified":"2026-09-23T01:24:20+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/"},"wordCount":2385,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/","url":"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/","name":"Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-09-22T18:10:00+00:00","dateModified":"2026-09-23T01:24:20+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/global-alzheimers-disease-biomarker-market-poised-for-phenomenal-expansion-at-a-growth-rate-of-9-by-2034-delveinsight\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Global Alzheimer\u2019s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/85409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=85409"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/85409\/revisions"}],"predecessor-version":[{"id":85411,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/85409\/revisions\/85411"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85410"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=85409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=85409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=85409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}